

Article

**Discovery of *N*-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A novel negative allosteric modulator of metabotropic glutamate receptor subtype 5 selected for clinical evaluation**

Andrew S Felts, Alice L Rodriguez, Anna L Blobaum, Ryan D. Morrison, Brittney S Bates, Analisa Thompson Gray, Jerri M. Rook, Mohammed N. Tantawy, Frank W Byers, Sichen Chang, Daryl F Venable, Vincent B Luscombe, Gilles D Tamagnan, Colleen M Niswender, J. Scott Daniels, Carrie K. Jones, P. Jeffrey Conn, Craig W Lindsley, and Kyle A Emmitte

*J. Med. Chem.*, **Just Accepted Manuscript** • Publication Date (Web): 22 May 2017

Downloaded from <http://pubs.acs.org> on May 23, 2017

**Just Accepted**

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



**ACS Publications**

# Discovery of *N*-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A novel negative allosteric modulator of metabotropic glutamate receptor subtype 5 selected for clinical evaluation

Andrew S. Felts<sup>†</sup>, Alice L. Rodriguez<sup>†</sup>, Anna L. Blobaum<sup>†</sup>, Ryan D. Morrison<sup>†</sup>, Brittney S. Bates<sup>†</sup>, Analisa Thompson Gray<sup>†</sup>, Jerri M. Rook<sup>†</sup>, Mohammed N. Tantawy<sup>±</sup>, Frank W. Byers<sup>†</sup>, Sichen Chang<sup>†</sup>, Daryl F. Venable<sup>†</sup>, Vincent B. Luscombe<sup>†</sup>, Gilles D. Tamagnan<sup>‡</sup>, Colleen M. Niswender<sup>†</sup>, J. Scott Daniels<sup>†</sup>, Carrie K. Jones<sup>†</sup>, P. Jeffrey Conn<sup>†</sup>, Craig W. Lindsley<sup>†,§</sup> and Kyle A. Emmitte<sup>\*,†,§,#</sup>

<sup>†</sup> Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232

<sup>§</sup> Department of Chemistry, Vanderbilt University, Nashville, TN 37232

<sup>±</sup> Department of Radiology and Radiological Sciences, Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN 37232

<sup>‡</sup> Molecular NeuroImaging, a division of inviCRO, New Haven, CT, 06510

**KEYWORDS.** *Metabotropic glutamate receptor subtype 5 (mGlu<sub>5</sub>), negative allosteric modulator (NAM), major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, obsessive-compulsive disorder (OCD), picolinamide*

**ABSTRACT.**

Preclinical evidence in support of the potential utility of mGlu<sub>5</sub> NAMs for the treatment of a variety of psychiatric and neurodegenerative disorders is extensive, and multiple such molecules have entered clinical trials. Despite some promising results from clinical studies, no small molecule mGlu<sub>5</sub> NAM has yet to reach market. Here we present the discovery and evaluation of *N*-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (**27**, VU0424238), a compound selected for clinical evaluation. Compound **27** is more than 900-fold selective for mGlu<sub>5</sub> versus the other mGlu receptors, and binding studies established a K<sub>i</sub> value of 4.4 nM at a known allosteric binding site. Compound **27** had a clearance of 19.3 and 15.5 mL/min/kg in rats and cynomolgus monkeys, respectively. Imaging studies using a known mGlu<sub>5</sub> PET ligand demonstrated 50% receptor occupancy at an oral dose of 0.8 mg/kg in rats and an intravenous dose of 0.06 mg/kg in baboons.

## INTRODUCTION


The metabotropic glutamate (mGlu) receptors are an eight-membered family of class C G protein-coupled receptors (GPCRs) that are activated by L-glutamic acid, the major excitatory neurotransmitter of the mammalian central nervous system (CNS). Further stratification of the mGlu receptors is made based on a variety of considerations, including structure, downstream signaling partners, and pharmacology. Whereas group I mGlu receptors (mGlu<sub>1</sub> and mGlu<sub>5</sub>) are found in post-synaptic locations and couple via G<sub>q</sub> to the activation of phospholipase C (PLC), both group II (mGlu<sub>2-3</sub>) and group III (mGlu<sub>4</sub> and mGlu<sub>6-8</sub>) receptors are found mainly in pre-synaptic locations and couple via G<sub>i</sub>/G<sub>o</sub> to the inhibition of adenylyl cyclase activity. Common to all mGlu receptors are a seven transmembrane (7TM)  $\alpha$ -helical domain that connects to a large bi-lobed extracellular amino-terminal domain, sometimes termed the “venus fly trap (VFT)” domain. Located within this VFT domain is the binding site for the native ligand; however, allosteric binding sites for small molecules have thus far been confined to the transmembrane domain. The structural and functional properties of the mGlu receptors have been reviewed extensively.<sup>1,2</sup>

In the search for compounds that are sufficiently selective for individual mGlu receptor subtypes, we have found allosteric modulation to be a successful approach. In fact, in many cases, such a strategy can be employed for the design of both positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs) of the same receptor.<sup>3</sup> Among the most actively investigated and advanced areas within this field is that of mGlu<sub>5</sub> NAMs.<sup>4,5</sup> Potential therapeutic applications for small molecule mGlu<sub>5</sub> NAMs are extensive and include addiction,<sup>6</sup> Alzheimer’s disease (AD),<sup>7</sup> anxiety,<sup>8</sup> autism spectrum disorder (ASD),<sup>9</sup> fragile X syndrome (FXS),<sup>10</sup> the levodopa-induced dyskinesia (LID) experienced by many patients with Parkinson’s

disease (PD),<sup>11,12</sup> major depressive disorder (MDD),<sup>13</sup> and obsessive-compulsive disorder (OCD).<sup>14</sup> Much of the preclinical work that has served to establish mGlu<sub>5</sub> antagonism as an exciting new mechanism for targeting these various conditions has been conducted with two related tool compounds, methyl-6-(phenylethynyl)-pyridine (**1**, MPEP)<sup>15</sup> and 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (**2**, MTEP)<sup>16</sup> (**Fig. 1**). Both compounds are structurally similar disubstituted alkynes, a motif that has been exploited for the design of several other highly optimized mGlu<sub>5</sub> NAM compounds.<sup>4,5</sup> While results from clinical studies have been reported with non-alkyne based mGlu<sub>5</sub> NAMs such as **3** (fenobam),<sup>17,18</sup> **4** (AZD9272),<sup>19,20</sup> and **5** (AZD2066),<sup>19,20</sup> the most highly studied and advanced clinical compounds are three alkyne mGlu<sub>5</sub> NAMs: **6** (mavoglurant),<sup>14,21-25</sup> **7** (basimglurant),<sup>26-29</sup> and **8** (dipraglurant)<sup>30,31</sup> (**Fig. 1**). Still, failures to reach primary clinical end points with **6**<sup>14,22,23</sup> and **7**<sup>28</sup> point to the continued need for highly optimized mGlu<sub>5</sub> NAMs. It should be noted that a recent report from Pfizer has described cutaneous toxicities in cynomolgus monkey toxicology studies with three structurally related non-alkyne based mGlu<sub>5</sub> NAMs.<sup>32</sup> Given that other mGlu<sub>5</sub> NAMs that are not structurally related to the Pfizer compounds have been used in long-term, repeat dose studies in non-human primates (NHPs)<sup>33,34</sup> and humans<sup>14,22-24,28</sup> without notes of a similar significant toxicity, it seems reasonable that such effects are not endemic to the mechanism. Still, these results make a compelling argument for using cynomolgus monkeys as the non-rodent species for toxicology studies in the event that our conclusion is incorrect.

Alkynes are potentially reactive functional groups. Pfizer has reported an instance of biliary epithelial hyperplasia in a NHP toxicology study with an alkyne-based mGlu<sub>5</sub> NAM developed by Wyeth.<sup>35</sup> This toxicity was believed to be linked to the reactivity of the alkyne based on metabolic studies that revealed extensive glutathione conjugation.<sup>35</sup> While this type of

biotransformation does not always manifest in humans with alkyne-containing compounds,<sup>25,27</sup> many research groups have sought to design novel mGlu<sub>5</sub> NAMs that are outside of this chemotype.<sup>4,5</sup> We have actively pursued a variety of approaches toward that end over the last decade.<sup>36,37</sup> For example, we conducted a high-throughput screen (HTS) of a collection of 160,000 compounds that identified multiple distinct mGlu<sub>5</sub> NAM hits. This same platform functions as our primary assay for lead optimization by measuring the ability of novel compounds to block the mobilization of calcium induced by an EC<sub>80</sub> concentration of glutamate in HEK293A cells that express rat mGlu<sub>5</sub>.




**Figure 1.** Prototypical mGlu<sub>5</sub> NAM preclinical tools **1** and **2** and clinically investigated mGlu<sub>5</sub> NAMs **3-8**.

## RESULTS AND DISCUSSION

**Initial analogs.** Recently, we described the discovery of an *in vivo* tool compound **9** (VU0409106)<sup>37-40</sup> that resulted from the optimization of one of these HTS hits (**Table 1**). That report focused exclusively on compounds with a benzamide core;<sup>37</sup> however, we were also interested in exploring picolinamide analogs as well (**10-13**, **Table 1**). Moving from the 3-fluorophenyl benzamide core (**9**) to an unsubstituted picolinamide core (**10**) reduced potency by approximately 8-fold; however, substitution of the picolinamide core at the 6-position with a methyl group (**11**) improved potency. In addition, structure-activity relationships (SAR) established in the benzamide series<sup>37</sup> translated to the picolinamides in the form of enhanced potency with the 5-fluoropyridin-3-yl ether (**12**). Once again, 6-methyl substitution of the picolinamide core (**13**) improved potency relative to the unsubstituted analog **12**. Buoyed by the encouraging results from this limited set of analogs and in search of a compound that represented a step forward from **9** to a compound worthy of advancement to clinical development, we devised a plan to prepare additional 6-alkyl-picolinamide analogs. Herein, we report the successful execution of that strategy.

**Table 1.** Initial picolinamide core analogs of **9**


			
No.	mGlu <sub>5</sub> pIC <sub>50</sub> (± SEM) <sup>a</sup>	mGlu <sub>5</sub> IC <sub>50</sub> (nM) <sup>a</sup>	% Glu Max <sup>a,b</sup>
<b>9</b>	7.62 ± 0.03	24	1.2 ± 0.1
<b>10</b>	6.70 ± 0.15	200	1.2 ± 0.1
<b>11</b>	7.01 ± 0.09	98	1.3 ± 0.1
<b>12</b>	7.22 ± 0.23	60	1.4 ± 0.1
<b>13</b>	8.01 ± 0.16	10	1.3 ± 0.1

<sup>a</sup> Calcium mobilization mGlu<sub>5</sub> assay; values are average of n ≥ 3 independent experiments

<sup>b</sup> Amplitude of response in the presence of 30  $\mu$ M test compound as a percentage of maximal response (100  $\mu$ M glutamate); average of  $n \geq 3$  independent experiments

**Synthesis of Compounds.** The synthetic routes to the picolinamide analogs largely mirror those described for the benzamide mGlu<sub>5</sub> NAMs.<sup>37</sup> Briefly, 4-nitropyridine-*N*-oxides **14** were refluxed in concentrated hydrochloric acid to afford 4-chloropyridine-*N*-oxides **16** (Scheme 1). Alternatively, 4-chloropyridines **15** were oxidized with hydrogen peroxide-urea adduct in the presence of trifluoroacetic acid to provide **16**. Treatment of **16** with trimethylsilyl cyanide and dimethylcarbamyl chloride generated 2-cyanopyridines **17**. A nucleophilic aromatic substitution reaction between heteroaryl alcohols **18** and **17** was employed to generate ether products **19**. Hydrolysis of the nitrile moieties of **19** was accomplished via thermal heating with aqueous sodium hydroxide solution to give the penultimate intermediate acids **20**. Coupling with the appropriate primary heteroaryl amines ( $H_2NR^4$ ) generated the target analogs.

**Scheme 1.** Synthesis of picolinamide analogs **10–13** and **21–37**<sup>a</sup>



<sup>a</sup> Reagents and conditions:  $R^1 = H, Me, CHF_2$ ;  $R^2 = H, Me, C_3H_5$ ;  $A = N, CH, CF, CCl$ ;  $R^4 = 4$ -methylthiazol-2-yl or substituted pyridin-2-yl; (a) con. HCl, reflux, 53-75%; (b)  $H_2O_2$ -urea,  $(F_3CCO)_2O$ , THF, 0  $^{\circ}C$  to r.t., 44-99%; (c)  $Me_3SiCN$ ,  $CH_2Cl_2$ ,  $Me_2NCOCl$ , 75-86%; (d) **18**,



$K_2CO_3$ , DMF, 80 °C, 45-77%; (e) 2N aq. NaOH, dioxane, reflux, 82-99%; (f)  $H_2NR^4$ ,  $POCl_3$ , pyridine, -15 °C, 22-81%.

**Initial SAR.** Even though compound **9** is a useful tool for acute behavioral studies in mice and rats,<sup>37,39</sup> it has several properties that prevent its further development. In particular, **9** has moderate to high clearance in rats ( $Cl_p$  43 mL/min/kg) and cynomolgus monkeys ( $Cl_p$  24 mL/min/kg).<sup>40</sup> In addition, **9** has poor bioavailability following oral administration in rats ( $F < 5\%$ ), and is an inhibitor of CYP1A2 ( $IC_{50} < 100$  nM). Evaluation of the picolinamide analogs of **9** indicated that the 4-methylthiazol-2-yl amide contributed substantially to the potent inhibition of CYP1A2 (e.g., **10** CYP1A2  $IC_{50} < 100$  nM), and SAR for mGlu<sub>5</sub> activity within the benzamide series showed limited tolerance for even subtle modifications on the thiazol-2-yl moiety.<sup>37</sup> Fortunately, analogs with a pyridin-2-yl replacement for the thiazol-2-yl ring appeared more amenable to substitution, and initial work in the picolinamide series was carried out in that context while taking advantage of SAR knowledge gained from the benzamide work (**Table 2**).

**Table 2.** Substituted 2-pyridyl amine analogs

No.	Series	R	mGlu <sub>5</sub> pIC <sub>50</sub> (± SEM) <sup>a</sup>	mGlu <sub>5</sub> IC <sub>50</sub> (nM) <sup>a</sup>	% Glu Max <sup>a,b</sup>	Protein Binding ( $f_u$ ) <sup>c</sup>		P450 Inhibition IC <sub>50</sub> (μM) <sup>d</sup>			
						rat	human	3A4	2D6	2C9	1A2
21	A	6-Me	7.70 ± 0.04	20	1.4 ± 0.1	0.076	0.066	>30	>30	4.1	2.4
22	B	6-Me	8.04 ± 0.12	9.1	1.4 ± 0.1	0.028	0.016	>30	>30	1.3	0.3
23	A	6-Et	8.03 ± 0.07	9.3	1.5 ± 0.2	0.027	0.034	>30	>30	1.8	0.9
24	B	6-Et	7.49 ± 0.31	32	1.2 ± 0.1	0.010	0.005				
25	A	6-F	7.94 ± 0.21	11	1.3 ± 0.1	ND <sup>e</sup>	0.132	>30	>30	1.8	0.6
26	B	6-F	8.45 ± 0.11	3.6	1.4 ± 0.1	ND <sup>e</sup>	0.023	8.0	>30	1.8	0.1

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

27	A	5-F	7.97 ± 0.05	11	1.6 ± 0.1	0.106	0.120	>30	>30	12.1	1.0
28	B	5-F	8.51 ± 0.04	3.1	1.2 ± 0.1	0.015	0.011	4.3	>30	5.4	0.2
29	A	5-Cl	8.17 ± 0.14	6.8	1.3 ± 0.1	0.067	0.049	16.4	>30	11.0	0.9
30	B	5-Cl	8.02 ± 0.16	9.6	1.3 ± 0.1			2.0	>30	>30	<0.1
31	A	4-F	7.27 ± 0.22	54	1.6 ± 0.3			>30	>30	>30	6.0
32	B	4-F	7.72 ± 0.13	19	1.3 ± 0.2			27.4	>30	5.7	0.4

<sup>a</sup> Calcium mobilization mGlu<sub>5</sub> assay; values are average of n ≥ 3 independent experiments

<sup>b</sup> Amplitude of response in the presence of 30 μM test compound as a percentage of maximal response (100 μM glutamate); average of n ≥ 3 independent experiments

<sup>c</sup> *f*<sub>u</sub> = fraction unbound; equilibrium dialysis assay

<sup>d</sup> Assayed in pooled HLM in the presence of NADPH with CYP-specific probe substrates


<sup>e</sup> Compound was unstable in rat plasma

As expected, the majority of these pyridin-2-yl analogs (**21-32**) proved to be potent antagonists of mGlu<sub>5</sub> on par with their thiazol-2-yl analogs (**11** and **13**). In a majority of instances, analogs with the 5-fluoropyridin-3-yl ether exhibited slightly superior mGlu<sub>5</sub> potency compared to the pyrimidin-5-yl ether analogs; however, the 6-ethylpyridin-2-yl analogs **23** and **24** and 5-chloropyridin-2-yl derivatives **29** and **30** were an exception to this trend. Assays that measured the degree of binding to rat and human plasma and a human liver microsomes (HLM) cocktail assay with probe substrates for four common P450s<sup>41</sup> were used to profile several selected compounds. SAR with regard to the heteroaryl ether group was clear as the pyrimidin-5-yl ether (Series A) analogs were consistently less bound to plasma than their 5-fluoropyridin-3-yl ether (Series B) analogs. No activity at 30 μM test compound was noted with regard to inhibition of CYP2D6, and inhibition of CYP3A4 and CYP2C9 ranged considerably. As anticipated, the most consistently potent P450 inhibition was observed with CYP1A2; however, there was another clear SAR with respect to the heteroaryl ether group. In this case, the pyrimidin-5-yl ether (Series A) analogs were less potent CYP1A2 inhibitors than the 5-fluoropyridin-3-yl ether (Series B) analogs.

Moving our attention to other portions of the chemotype, we prepared further analogs that revealed additional SAR. Modifications made in the context of the 5-fluoropyridin-2-yl amide

found in analogs **27** and **28** are depicted here (**Table 3**). Installation of a methyl group at the 2-position of the pyrimidin-5-yl ether (**33**) resulted in a 3-fold loss in potency relative to **27**. While this modification increased the extent of binding to plasma, it also reduced inhibition versus CYP1A2 and CYP2C9. Moving to a larger cyclopropyl group at the 2-position of the pyrimidin-5-yl ether (**34**) substantially eroded potency at mGlu<sub>5</sub>, indicating minimal tolerance for steric bulk at this position. Likewise, replacement of the 6-methyl group on the picolinamide core with a difluoromethyl group (**35**) led to an approximately 5-fold loss in mGlu<sub>5</sub> potency, illustrating little tolerance for modification at that position. Replacement of the 5-fluoro group of the pyridin-3-yl of **28** with a 5-chloro group (**36**) resulted in only a slight drop in potency. Replacement of the meta-halogen atoms found in **28** and **36** with the para-methyl group in 6-methylpyridin-3-yl ether **37** reduced mGlu<sub>5</sub> potency by 50 and 20-fold, respectively.

**Table 3.** Analogs of compound **27** and **28**

 <div style="display: flex; justify-content: space-around; margin-top: 10px;"> <div> <p><b>27</b> R = H</p> <p><b>33</b> R = Me</p> <p><b>34</b> R = C<sub>3</sub>H<sub>5</sub></p> </div> <div> <p><b>35</b></p> </div> <div> <p><b>28</b> R = F</p> <p><b>36</b> R = Cl</p> </div> <div> <p><b>37</b></p> </div> </div>									
No.	mGlu <sub>5</sub> pIC <sub>50</sub> (± SEM) <sup>a</sup>	mGlu <sub>5</sub> IC <sub>50</sub> (nM) <sup>a</sup>	% Glu Max <sup>a,b</sup>	Protein Binding (f <sub>u</sub> ) <sup>c</sup>		P450 Inhibition IC <sub>50</sub> (μM) <sup>d</sup>			
				rat	human	3A4	2D6	2C9	1A2
<b>27</b>	7.97 ± 0.05	11	1.6 ± 0.1	0.106	0.120	>30	>30	12.1	1.0
<b>33</b>	7.48 ± 0.04	33	1.5 ± 0.2	0.081	0.074	>30	>30	>30	>30
<b>34</b>	6.60 ± 0.25	251	1.5 ± 0.1						
<b>35</b>	7.32 ± 0.02	48	1.3 ± 0.1						
<b>28</b>	8.51 ± 0.04	3.1	1.2 ± 0.1	0.015	0.011	4.3	>30	5.4	0.2
<b>36</b>	8.14 ± 0.27	7.2	1.0 ± 0.1	0.058	0.014	3.8	>30	21.5	0.2
<b>37</b>	6.80 ± 0.11	158	1.2 ± 0.1						

<sup>a</sup> Calcium mobilization mGlu<sub>5</sub> assay; values are average of n ≥ 3 independent experiments

<sup>b</sup> Amplitude of response in the presence of 30 μM test compound as a percentage of maximal response (100 μM glutamate); average of n ≥ 3 independent experiments

<sup>c</sup> f<sub>u</sub> = fraction unbound; equilibrium dialysis assay

<sup>d</sup> Assayed in pooled HLM in the presence of NADPH with CYP-specific probe substrates

***In vivo* Pharmacokinetics (PK) Studies.** Previous studies in our laboratories with pyrimidin-5-yl ethers identified this ring as a substrate for aldehyde oxidase (AO)-mediated metabolism.<sup>38,40</sup> Thus, given the likelihood that several of our interesting new compounds would be subject to non-P450 mediated metabolism, we decided to move directly into an *in vivo* setting to evaluate the clearance of a variety of select analogs (**Table 4**). In these studies, the three analogs with the 5-fluoropyridin-2-yl amide group (**27**, **28**, and **33**) exhibited superior profiles compared to the other compounds that contained pyridin-2-yl amides with 6-alkyl (**21-23**) or 6-fluoro (**26**) groups. The plasma clearance of **26** was greater than hepatic blood flow,<sup>42</sup> which suggests that the instability previously observed in rat plasma for this compound (**Table 2**) is not merely an *in vitro* phenomenon. Blocking the 2-position of pyrimidin-5-yl ether (**33**) reduced clearance and lengthened mean residence time relative to unsubstituted analog **27**. Such a result points toward this position as one potential site for metabolism, which is consistent with prior studies on related analog **9**.<sup>38,40</sup> Compounds **27**, **28**, and **33** were subsequently evaluated in tissue distribution studies (**Table 5**) using oral dosing. Acceptable CNS penetration was achieved with all three compounds, and unbound brain to unbound plasma ratios ( $K_{p,uu}$ ) were near unity with **27** and **28**, indicating distribution equilibrium between the compartments and a low probability of these two compounds being substrates for transporters in rats.<sup>43</sup> The  $K_{p,uu}$  observed for **33** raises the possibility of active transport with this compound; however, additional studies would be required to conclusively determine if that was indeed the case. All compounds achieved unbound brain levels in excess of their respective mGlu<sub>5</sub> functional potency at the dose used in these experiments (10 mg/kg). Compounds **27** and **28** were particularly attractive from this perspective, reaching unbound brain levels of 18- and 10-fold over their functional potency, respectively.

**Table 4.** Preliminary rat PK results using intravenous (IV) dosing<sup>a</sup>

No.	mGlu <sub>5</sub> IC <sub>50</sub> (nM) <sup>b</sup>	<i>t</i> <sub>1/2</sub> (min) <sup>c</sup>	MRT (min) <sup>c</sup>	Cl <sub>p</sub> (mL/min/kg) <sup>c</sup>	V <sub>ss</sub> (L/kg) <sup>c</sup>
21 <sup>d</sup>	20	105	39	34.2	1.6
22 <sup>e</sup>	9.1	268	120	32.5	4.5
23 <sup>f</sup>	9.3	404	80	43.7	6.6
26 <sup>d</sup>	3.6	82	157	96	11
27 <sup>d</sup>	11	390	93	19.3	1.8
28 <sup>d</sup>	3.1	281	208	9.2	1.9
33 <sup>f</sup>	33	229	191	6.2	1.2

<sup>a</sup> Average n = 2, male Sprague-Dawley rats; dose = 1.0 mg/kg<sup>b</sup> Calcium mobilization mGlu<sub>5</sub> assay; values are average of n ≥ 3 independent experiments<sup>c</sup> *t*<sub>1/2</sub> = terminal phase plasma half-life; MRT = mean residence time; Cl<sub>p</sub> = plasma clearance; V<sub>ss</sub> = volume of distribution at steady-state<sup>d</sup> Vehicle = 10% EtOH, 70% PEG 400, 20% saline<sup>e</sup> Vehicle = 10% EtOH, 60% PEG 400, 30% saline<sup>f</sup> Vehicle = 10% EtOH, 50% PEG 400, 40% saline**Table 5.** Tissue distribution studies using oral dosing<sup>a</sup>


No.	mGlu <sub>5</sub> IC <sub>50</sub> (nM) <sup>b</sup>	Protein Binding ( <i>f</i> <sub>u</sub> ) <sup>c</sup>		Total plasma (nM)	Total brain (nM)	Unbound plasma (nM)	Unbound brain (nM)	K <sub>p</sub> <sup>d</sup>	K <sub>p,uu</sub> <sup>e</sup>	Unbound brain / mGlu <sub>5</sub> IC <sub>50</sub>
		plasma	brain							
27	11	0.106	0.078	3000	2580	318	201	0.86	0.63	18
28	3.1	0.015	0.011	2570	2870	38.6	31.6	1.1	0.82	10
33	33	0.081	0.044	4820	3220	390	142	0.67	0.36	4.3

<sup>a</sup> Average n = 2, male Sprague-Dawley rats; dose = 10 mg/kg; vehicle = 10% polysorbate 80 in 0.5% methyl cellulose; t = 1 h post dose<sup>b</sup> Calcium mobilization mGlu<sub>5</sub> assay; values are average of n ≥ 3 independent experiments<sup>c</sup> *f*<sub>u</sub> = fraction unbound; equilibrium dialysis assay; brain = mouse brain homogenates<sup>d</sup> K<sub>p</sub> = total brain to total plasma ratio<sup>e</sup> K<sub>p,uu</sub> = unbound brain (brain *f*<sub>u</sub> · total brain) to unbound plasma (plasma *f*<sub>u</sub> · total plasma) ratio

Considering their favorable profiles, compounds **27** and **28** were selected for oral pharmacokinetic and bioavailability studies in rats and cynomolgus monkeys (**Table 6**). Cynomolgus monkeys were chosen as a second preclinical species as it has been established that AO activity varies across species. Specifically, AO activity is highest in humans and NHPs, moderate in rats, and undetectable in dogs.<sup>44</sup> Using *in vitro* methods described previously for **9**,<sup>38,40</sup> we confirmed that AO contributed significantly to the metabolism of **27** in rats, cynomolgus monkey, and human hepatic S9 fractions (**Fig. 2**). Oral exposure was significant as

bioavailability exceeded 50% with both compounds in rats. Compound **27** exhibited an earlier and slightly higher plasma  $C_{max}$  than **28**; however, the lower clearance of **28** resulted in prolonged exposure and larger area under the curve (AUC) than observed for **27**. The PK results from analogous studies in cynomolgus monkeys showed these compounds to be similar in that both compounds showed clearance approximately one-third of hepatic blood flow.<sup>42</sup> Bioavailability, while lower than that observed in rats, was still greater than 30% in each case. With largely attractive *in vivo* PK profiles, both compounds were advanced into further studies to identify additional factors for differentiation.


Table 6. Rat and cynomolgus monkey pharmacokinetics of compounds **27** and **28**<sup>a</sup>



<sup>a</sup> Oral vehicle = 10% polysorbate 80 in 0.5% methyl cellulose; IV vehicle = 10% EtOH, 70% PEG 400, 20% saline

<sup>b</sup> average n = 2 male Sprague-Dawley rats

<sup>c</sup>  $t_{1/2}$  = terminal phase plasma half-life; MRT = mean residence time;  $Cl_p$  = plasma clearance;  $V_{ss}$  = volume of distribution at steady-state  
<sup>d</sup>  $T_{max}$  = time at which maximum concentration occurs;  $C_{max}$  = maximum concentration; AUC = area under the curve; F = bioavailability  
<sup>e</sup> average n = 2 male cynomolgus monkeys



**Figure 2.** Metabolite (**38**) of **27** identified in rat, cynomolgus monkey, and human hepatic S9 fractions that is produced predominately by AO.


**Ancillary pharmacology.** To judge the selectivity of these analogs versus the other members of the mGlu receptor family, the effects of both **27** and **28** at 10  $\mu$ M on the orthosteric agonist concentration response curve (CRC) was measured in fold-shift experiments.<sup>45,46</sup> No significant effects on the agonist CRC were noted with either compound, indicating excellent selectivity for mGlu<sub>5</sub>. To assess potential ancillary pharmacology, both compounds were screened at 10  $\mu$ M in a commercial radioligand binding assay panel of 68 diverse and clinically relevant targets.<sup>47</sup> While **27** had no significant responses at any target, where significant responses are defined as inhibition of more than 50% of radioligand binding, one significant response of 86% inhibition was noted for **28** at the dopamine transporter (DAT). For comparison, **27** only inhibited DAT at a level of 34%. A subsequent CRC was obtained, and **28** was found to inhibit radioligand binding with an  $IC_{50}$  of 1.54  $\mu$ M. Since inhibition of DAT is associated with abuse potential,<sup>48</sup> we next evaluated **28** in a functional cell-based assay that measured inhibition of dopamine uptake.<sup>49</sup> Indeed, consistent with results obtained from the binding assay, **28** exhibited an  $IC_{50}$  of 1.38  $\mu$ M in this assay. While **28** is more than 400-fold selective for mGlu<sub>5</sub> versus DAT, the lack of

concern regarding this target in the case of **27** was viewed as a positive for that compound. With its preferable P450 inhibition profile (**Table 2**) and the higher unbound brain concentrations achieved in rats also in its favor, the decision was made to proceed with additional detailed characterization of **27**.

**Detailed characterization of 27.** Having narrowed our interest to analog **27**, we carried out a more thorough characterization of its interaction with mGlu<sub>5</sub> (**Fig. 3**). First, to ensure that there was no appreciable species difference in the mGlu<sub>5</sub> activity of **27**, we carried out our calcium mobilization assay in HEK293A cells expressing the human receptor (**Fig. 3A**). As anticipated, the potency difference between rat (IC<sub>50</sub> = 11 nM) and human mGlu<sub>5</sub> (IC<sub>50</sub> = 14 nM) was negligible. To study the effects of **27** on mGlu<sub>5</sub> activity in a native system, experiments in rat cortical astrocytes were conducted (**Fig. 3B**). As expected, **27** induced a concentration-dependent rightward shift of the glutamate CRC and decreased the maximal response to glutamate. To investigate whether **27** interacted with the mGlu<sub>5</sub> allosteric site that is common to many mGlu<sub>5</sub> NAMs such as **1** and **2** (**Fig. 1**), we also carried out a competition radioligand binding assay with [<sup>3</sup>H]-3-methoxy-5-(pyridin-2-ylethynyl)pyridine (**39**)<sup>50</sup> (**Fig. 3C**) in membranes prepared from HEK293A cells expressing rat mGlu<sub>5</sub>. This study confirmed the interaction of **27** with this known binding site (mGlu<sub>5</sub> K<sub>i</sub> = 4.4 nM). We also performed saturation binding experiments with increasing concentrations of [<sup>3</sup>H]-**38** in the presence and absence of multiple concentrations of **27** (**Fig. 3D/E**). Increasing concentrations of **27** had no effect on the B<sub>max</sub> of the radioligand, but increased the K<sub>d</sub> as shown (**Fig. 3D**), a finding that suggests a competitive interaction between **27** and [<sup>3</sup>H]-**39**. Scatchard analysis (**Fig. 3E**) of the results plotting bound/free versus bound ligand demonstrated that addition of **27** induced a change in slope of the regression line



(change in  $K_d$ ) but had no effect on the x-intercept (no change in  $B_{max}$ ). These data are consistent with **27** competitively displacing [ $^3H$ ]-**39** at the aforementioned known allosteric binding site. A final set of radioligand kinetic binding experiments was conducted that examined the effect of **27** on the dissociation of [ $^3H$ ]-**38**. In these studies, neither concentration (300 nM or 100 nM) of **27** had any effect on the dissociation rate of the radioligand (data not shown), a result consistent with prior studies and a competitive interaction. Lastly, we examined the effects of increasing concentrations of the mGlu<sub>5</sub> neutral site ligand 5-methyl-6-(phenylethynyl)-pyridine (**40**)<sup>51</sup> on the calcium mobilization CRC of **27** in HEK293A cells expressing rat mGlu<sub>5</sub> (**Fig. 3F**). In these experiments, **40** induced a parallel rightward shift in the **27** concentration response relationship, which is consistent with **40** competing for the known allosteric binding site with **27**. Furthermore, a Schild analysis (data not shown) of the effects of **40** on the **27** concentration response yielded a linear regression with a slope of 0.96, indicating the relationship between the two compounds was competitive. Extrapolation of the line to the x-intercept established a  $K_i$  of approximately 240 nM, a result consistent with the  $K_i$  value for **40** at the [ $^3H$ ]-**39** site as described in the literature (388 nM).<sup>51</sup> Each of these studies combine to conclusively establish that **27** binds in a competitive manner to the aforementioned known mGlu<sub>5</sub> allosteric binding site.



**Figure 3.** (A) Ca<sup>2+</sup> mobilization assay CRC for **27** in HEK293A cells expressing human mGlu<sub>5</sub>; (B) Effects of **27** on glutamate CRC in rat cortical astrocytes; (C) Competition radioligand binding CRC with **27** and [<sup>3</sup>H]-3-methoxy-5-(pyridin-2-ylethynyl)pyridine (**39**); (D) Saturation binding experiment: increasing concentrations of [<sup>3</sup>H]-**39** in the presence and absence of multiple concentrations of **27**; (E) Saturation binding experiment: Scatchard analysis of bound/free versus bound ligand; (F) Effects of the neutral mGlu<sub>5</sub> site ligand 5-methyl-6-(phenylethynyl)-pyridine (**40**) on the functional inhibition of glutamate responses induced by **27**.

With a detailed understanding of the pharmacology of **27** in hand, we moved the compound into a host of additional assays designed to identify potential risks for clinical development (Table 7). Permeability and potential for P-glycoprotein (P-gp) mediated efflux was assessed in both Madin-Darby canine kidney (MDCK) cells transfected with the human MDR1 gene<sup>52</sup> and human colon carcinoma derived Caco-2 cells.<sup>53</sup> Permeability was moderate, and efflux ratios

were near unity in both cell lines, indicating a low potential for transporter mediated efflux. A definitive and expanded assessment of the ability of **27** to reversibly inhibit the metabolism of isoform-selective probe substrates of P450s was conducted. Results were generally consistent with the preliminary results (**Table 2**) with moderate inhibition of CYP1A2 observed. In parallel to these studies, the potential for **27** to time-dependently inhibit each P450 was assessed with no evidence of time-dependent inhibition noted in any case. To shed further light on the likely human PK profile of **27**, the stability of the compound was assessed in human cryopreserved hepatocytes, a system which is potentially useful for evaluating compounds with non-P450 mediated routes of metabolism such as AO.<sup>54</sup> Gratifyingly, the predicted hepatic clearance in humans using this method was low with a half-life of more than 5 h. To assess any potential cardiac liabilities, **27** was subjected to a commercial ion channel panel.<sup>55</sup> Fortunately, no significant risks were identified in this panel. Finally, the potential mutagenic activity of **27** was investigated in the bacterial reverse mutation assay (Ames assay),<sup>56</sup> and no mutagenic responses were noted in any of the five strains either in the presence or absence of S9 metabolic activation. Encouraged by the overall profile of **27**, we advanced this compound to behavioral assays in the rat.

**Table 7.** Further *in vitro* characterization of **27**

Permeability assays			
Cell line	Papp (A-B)	Papp (B-A)	Efflux Ratio
MDCK-MDR1	6.2 x 10 <sup>-6</sup> cm/s	7.2 x 10 <sup>-6</sup> cm/s	1.2
Caco-2	6.5 x 10 <sup>-6</sup> cm/s	7.9 x 10 <sup>-6</sup> cm/s	1.2
Definitive P450 inhibition assays <sup>a</sup>			
P450	probe	IC <sub>50</sub> (μM)	
CYP3A4	midazolam	133 ± 23	
CYP3A4	testosterone	>200	
CYP2D6	(R)-bufuralol	>200	
CYP2C9	diclofenac	29.9 ± 7.3	
CYP2C19	(S)-mephenytoin	106 ± 10	

CYP2C8	amodiaquine	>200		
CYP2B6	efavirenz	>200		
CYP1A2	phenacetin	2.90 ± 0.72		
Stability in human cryopreserved hepatocytes				
intrinsic clearance (CL <sub>INT</sub> )		1.43 μL/min/million cells		
half-life ( <i>t</i> <sub>1/2</sub> )		322 min		
predicted hepatic clearance (CL <sub>HEP</sub> )		3.59 mL/min/kg		
Cardiac ion channel panel <sup>b</sup>				
ion channel	IC <sub>50</sub> (μM)	ion channel	IC <sub>50</sub> (μM)	
hERG	73.6	hCav1.2	>100	
hNav1.5 (tonic)	>100	hCav3.2	>100	
hNav1.5 (phasic)	>100	hKir2.1	>100	
hKv4.3	>100	hHCN2	>100	
hKv1.5	>100	hHCN4	>100	
Bacterial reverse mutation assay <sup>c</sup>				
TA98	TA100	WP2 <i>uvrA</i>	TA135	TA1537
negative	negative	negative	negative	negative


<sup>a</sup> Assayed in pooled HLM (with and without NADPH) using CYP-specific probe substrates

<sup>b</sup> Evaluated using IonWorks™ Quattro system

<sup>c</sup> With and without S9 metabolic activation

**Behavioral pharmacology.** It is well known that mice will bury foreign objects such as glass marbles in deep bedding. Likewise, pretreatment with low doses of benzodiazepines and multiple mGlu<sub>5</sub> NAM tool compounds have been shown to inhibit this behavior.<sup>57</sup> It has been argued recently that the marble burying assay models the repetitive and perseverative behavior associated with OCD as opposed to novelty-induced anxiety.<sup>58</sup> We have also employed this rapid assay that utilizes naïve mice as a frontline behavioral screen for our discovery programs directed toward mGlu<sub>5</sub> NAMs.<sup>36,37</sup> Using intraperitoneal (IP) dosing as a convenient route for rapidly and accurately dosing large numbers of animals, we examined the effects of **27** in this test (**Fig. 4A**). Dose-dependent effects on marble burying were observed, and all doses greater than or equal to 0.3 mg/kg produced significant effects relative to the vehicle control. The 3.0 mg/kg dose produced an effect on marble burying on par with the positive control **2** (15 mg/kg) in this study. A satellite experiment was conducted using the 3.0 mg/kg dose, and brain samples

were collected and analyzed for exposure of **27**. At 15 min post dose of **27**, which correlates to the initiation time point of the marble burying study, the total brain concentration of **27** was 1.48  $\mu\text{M}$ . Calculation of the unbound brain concentration using equilibrium dialysis data (**Table 5**) yields a level of 115 nM, which is approximately 10-fold more than the functional mGlu<sub>5</sub> activity.




**Figure 4.** (A) Dose-dependent inhibition of marble burying with **27**; vehicle = 10% polysorbate 80 (IP); male CD-1 mice; n = 10 per treatment group; 15 min pre-treatment; 30 min burying time; \*, p < 0.05 versus vehicle control group, Dunnett's test; bars denote marbles buried; (B) Dose-dependent inhibition of immobility in rats with **27**; vehicle = 10% polysorbate 80 (**27**, intraperitoneal) and sterile saline (ketamine, subcutaneous); male Sprague-Dawley rats; n = 8-10 per treatment group; 30 min pre-treatment; 6 min testing session; \*, p < 0.05 versus vehicle control group, Dunnett's test; bars denote duration of immobility in s.

Having observed efficacy in this model of anxiety/OCD, we next studied **27** in an animal model of depression as well. The forced swim test (FST) measures the duration of immobility observed in rats suspended in a tank of water from which they cannot escape.<sup>59</sup> Many clinical

antidepressants are able to reduce the time that the animals are immobile while increasing the time that they are active. Furthermore, certain mGlu<sub>5</sub> NAMs have also shown efficacy in this model of depression.<sup>60</sup> Examination of **27** in this assay showed a dose-dependent ability of the compound to reduce the duration of immobility indicative of antidepressant activity (**Fig. 4B**). This result compares favorably to the literature report for **7** in the same assay, where that compound had a minimum efficacious dose of 10 mg/kg (PO).<sup>60</sup> The high dose used in this study (30 mg/kg IP) produced an efficacy equivalent to that of the positive control, ketamine, a known antagonist of the *N*-methyl-D-aspartate (NMDA) receptor. Though ketamine is an older drug and produces undesirable psychotomimetic side effects, more recent clinical studies have shown that it can induce a rapid antidepressant effect in patients with treatment-resistant depression (TRD).<sup>61</sup> A report from last year implicated the activation of the  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor by a specific ketamine metabolite rather than direct antagonism of the NMDA receptor by ketamine as the potential source of these rapid antidepressant effects.<sup>62</sup> Interestingly, prior studies have shown that the antidepressant activity in the FST with mGlu<sub>5</sub> NAM **2** involved signaling through the NMDA but not the AMPA receptor.<sup>63</sup> Thus, the mechanisms by which ketamine and mGlu<sub>5</sub> NAMs illicit their antidepressant effects may well be distinct.

**Imaging studies.** Recognizing that an ability to study receptor occupancy (RO) in the clinic would represent a potential advantage for advancing **27**, we decided to investigate RO studies in preclinical species. [<sup>18</sup>F]-3-Fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile ([<sup>18</sup>F]-FPEB, [<sup>18</sup>F]-**41**)<sup>64</sup> is a close structural analog of radioligand [<sup>3</sup>H]-**38** that has been used both preclinically<sup>39</sup> and in the clinic<sup>64</sup> as a positron emission topography (PET) ligand for studying mGlu<sub>5</sub> RO. Thus, we

decided to carry out [ $^{18}\text{F}$ ]-**41**  $\mu\text{PET}$  studies with **27** in rats (**Fig. 5**). In these studies, **27** was dosed orally 30 min prior to IV dosing of [ $^{18}\text{F}$ ]-**41**. PET imaging was initiated and continued for 1 h. Representative images demonstrating dose-dependent displacement of [ $^{18}\text{F}$ ]-**41** by **27** are depicted in **Fig. 5A**. Maximum occupancy of 80% was achieved at 10 mg/kg **27** (**Fig. 5B**). Plasma samples were collected throughout the study. Plotting the maximum unbound plasma concentration of **27** versus RO resulted in an unbound level  $\text{Occ}_{50}$  of 13 nM (**Fig. 5C**). Plotting the dose of **27** versus the RO normalized to the maximum displacement of [ $^{18}\text{F}$ ]-**41** gave an  $\text{RO}_{50}$  of 0.8 mg/kg (**Fig. 5D**).




**Figure 5.** Imaging studies in rodents;  $n = 4\text{--}8$  Sprague-Dawley rats; **27** vehicle = 10% polysorbate 80 in 0.5% methyl cellulose; **27** dosed 30 min prior to [ $^{18}\text{F}$ ]-**41** (IV); (A) Representative images of [ $^{18}\text{F}$ ]-**41** by increasing oral doses of **27** (B) mGlu<sub>5</sub> RO obtained with [ $^{18}\text{F}$ ]-**41** and increasing oral doses of **27**; (C) Unbound maximum plasma concentration of **27**

versus mGlu<sub>5</sub> RO; (**D**) Dose of **27** versus mGlu<sub>5</sub> RO; \*normalized to the maximum displacement of [<sup>18</sup>F]-**41**.

Based on the RO results in rats, we next investigated whether similar results would be obtained in NHPs. As such, we advanced **27** into studies in baboons using the same radiotracer [<sup>18</sup>F]-**41** (**Fig. 6**). The design for this experiment was very similar to the aforementioned study in rats; however, in this case both **27** and the radiotracer were delivered via IV administration. There was a clear reduction in the uptake of [<sup>18</sup>F]-**41** relative to baseline that followed a dose-dependent relationship with **27** (**Fig. 6A, 6D, 6E**). The maximum dose resulted in 89% RO of mGlu<sub>5</sub>. Plasma samples were again taken throughout the study to analyze **27** levels, and RO was plotted against the plasma maximum to arrive at a total plasma Occ<sub>50</sub> of 56 nM (**Fig. 6B**). If one assumes that human and baboon plasma protein binding is similar, this equates to a plasma unbound Occ<sub>50</sub> of 6.7 nM, which is within two-fold of that observed in the rodent study. The effective IV dose that produces 50% RO (RO<sub>50</sub>) was determined to be 0.06 mg/kg (**Fig. 6C**).





**Figure 6.** Imaging studies in female baboons; subject A received three doses (0.01, 0.1, and 0.18 mg/kg); subject B received two doses (0.03 and 0.56 mg/kg); **27** vehicle = 10% ethanol, 30% PEG 400, 20% hydroxypropyl- $\beta$ -cyclodextrin in water; **27** dosed over 20 min, 30 min prior to [ $^{18}$ F]-**41** (IV, 3 min bolus) for all doses except the 0.18 mg/kg dose, which was dosed over 2 min, 50 min prior to [ $^{18}$ F]-**41**; (A) mGlu<sub>5</sub> RO obtained in two female baboons with [ $^{18}$ F]-**41** and increasing IV doses of **27**; (B) Total maximum plasma concentration of **27** versus mGlu<sub>5</sub> RO; (C) Dose of **27** versus mGlu<sub>5</sub> RO; (D) Images for subject A averaged from 0-150 min; (E) Images for subject B averaged from 0-180 min.

## CONCLUSION

Continuation of our mGlu<sub>5</sub> NAM discovery program that began with a cell-based HTS has culminated in the identification of the highly optimized compound **27** (VU0424238).<sup>65</sup>

Compound **27** is a highly potent and selective antagonist of mGlu<sub>5</sub> with a favorable preclinical profile. The molecule has low-moderate clearance and good oral bioavailability in two species. Compound **27** displays CNS penetration in rodents, and we believe that the compound is a low-risk for transporter-mediated efflux and drug-drug interactions. While the compound is a moderate inhibitor of CYP1A2, this aspect is considered manageable. Importantly, the compound is active in preclinical models of anxiety/OCD and depression, both of which are assays where mGlu<sub>5</sub> NAMs have shown activity in the past. Moreover, a clinically useful radiotracer has been used to demonstrate mGlu<sub>5</sub> RO by **27** in both rodents and NHPs. Based on the totality of data, we have selected **27** for advancement to clinical development including studies designed to enable an investigational new drug (IND) application. Here is the public disclosure of the chemical structure of **27**, our candidate for clinical studies. Future publications describing detailed metabolic profiling, chemical process development and formulation, and toxicology studies are under preparation and will be communicated in the near future.

## EXPERIMENTAL SECTION

### Synthetic Procedures and Characterization Data

**General.** All NMR spectra were recorded on a 400 MHz AMX Bruker NMR spectrometer. <sup>1</sup>H and <sup>13</sup>C chemical shifts are reported in δ values in ppm downfield with the deuterated solvent as the internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, b = broad, m = multiplet), integration, coupling constant (Hz). High resolution mass spectra were obtained on an Agilent 6540 UHD Q-TOF with ESI source. MS parameters were as follows: fragmentor: 150, capillary voltage: 3500 V, nebulizer pressure: 60 psig, drying gas flow: 13 L/min, drying gas temperature: 275 °C. Samples were introduced via

an Agilent 1200 UHPLC comprised of a G4220A binary pump, G4226A ALS, G1316C TCC, and G4212A DAD with ULD flow cell. UV absorption was observed at 215 nm and 254 nm with a 4 nm bandwidth. Column: Agilent Zorbax Extend C18, 1.8  $\mu$ m, 2.1 x 50 mm. Gradient conditions: 5% to 95% CH<sub>3</sub>CN in H<sub>2</sub>O (0.1% formic acid) over 1 min, hold at 95% CH<sub>3</sub>CN for 0.1 min, 0.5 mL/min, 40 °C.

**Purity.** Low resolution reverse phase LCMS analysis was used to assess compound purity at two wavelengths: 215 and 254 nm. All analogs were at least 95% pure according to this analysis. Low resolution reverse phase LCMS analysis was performed using an Agilent 1200 system comprising a binary pump with degasser, high-performance autosampler, thermostatted column compartment, diode-array detector (DAD) and a C18 column. Flow from the column was split to a 6130 SQ mass spectrometer and Polymer Labs ELSD. The MS detector was configured with an electrospray ionization source. Data acquisition was performed with Agilent Chemstation and Analytical Studio Reviewer software. Method 1: Samples were separated on a ThermoFisher Accucore C18 column (2.6  $\mu$ m, 2.1 x 30 mm) at 1.5 mL/min, with column and solvent temperatures maintained at 45 °C. The gradient conditions were 7% to 95% acetonitrile in water (0.1% TFA) over 1.4 min. Low-resolution mass spectra were acquired by scanning from 135 to 700 atomic mass units (AMU) in 0.25 s with a step size of 0.1 AMU and peak width of 0.03 min. Drying gas flow was 11 L/min at a temperature of 350 °C and a nebulizer pressure of 40 psi. The capillary needle voltage was 3000 V, and the fragmentor voltage was 100V. Method 2: Samples were separated on a ThermoFisher Accucore C18 column (2.6  $\mu$ m, 2.1 x 30 mm) at 1.5 mL/min, with column and solvent temperatures maintained at 45 °C. The gradient conditions were 7% to 95% acetonitrile in water (0.1% TFA) over 1.1 min. Low-resolution mass spectra were acquired by scanning from 135 to 700 AMU in 0.25 s with a step size of 0.1 AMU and

peak width of 0.03 min. Drying gas flow was 11 L/min at a temperature of 350 °C and a nebulizer pressure of 40 psi. The capillary needle voltage was 3000 V, and the fragmentor voltage was 100V. Method 3: Samples were separated on a Restek Aqueous C18 column (3  $\mu$ m, 3.2 x 30 mm) at 1.25 mL/min, with column and solvent temperatures maintained at 45 °C. The gradient conditions were 10% to 100% acetonitrile in water (0.1% TFA) over 2 min. Low-resolution mass spectra were acquired by scanning from 100 to 1500 AMU in 0.25 s with a step size of 0.1 AMU and peak width of 0.03 min. Drying gas flow was 11 L/min at a temperature of 350 °C and a nebulizer pressure of 40 psi. The capillary needle voltage was 3000 V, and the fragmentor voltage was 70V.

#### Preparation of compound 27.

**4-Chloro-2-methylpyridine-*N*-oxide (16a).** 2-methyl-4-nitropyridine 1-oxide **14a** (5.0 g, 32 mmol, 1.0 eq) was dissolved in concentrated HCl (80 mL) and refluxed for 3 days. The reaction was cooled, and the excess concentrated HCl was removed *in vacuo*. The viscous oil was neutralized with 10% K<sub>2</sub>CO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub> (5x). The combined organics were dried (MgSO<sub>4</sub>), filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel afforded 3.49 g (75%) of the title compound as a yellow solid.

*(Alternative Procedure)* 4-Chloro-2-methylpyridine **15a** (5.0 g, 39 mmol, 1.0 eq) and hydrogen peroxide-urea adduct (7.37 g, 78.4 mmol, 2.0 eq) were dissolved in THF (196 mL) and cooled to 0 °C. Trifluoroacetic anhydride (12 mL, 86.3 mmol, 2.2 eq) was added dropwise over 15 min, and the reaction was allowed to warm to room temperature. After determination of the completion of the reaction by LCMS (approximately 45 min), the reaction was cooled to 0 °C

and quenched with a 10% aqueous solution of sodium thiosulfate. The reaction was extracted with EtOAc (3x), dried (MgSO<sub>4</sub>), filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel afforded 5.63 g (99%) of the title compound as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 8.23 (d, *J* = 7.0 Hz, 1H), 7.66 (d, *J* = 3.0 Hz, 1H), 7.40 (dd, *J* = 7.0, 3.0 Hz, 1H), 2.32 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 149.53, 139.78, 128.73, 126.41, 124.17, 17.09 ppm; LCMS (Method 1): R<sub>T</sub> = 0.302 min, *m/z* = 144.2 [M+H]<sup>+</sup>; HRMS, calc'd for C<sub>6</sub>H<sub>6</sub>ClNO [M], 143.0138; found 143.0139.

**4-Chloro-6-methylpicolinonitrile (17a).** Compound **16a** (8.97 g, 62.5 mmol, 1.0 eq) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and dried over MgSO<sub>4</sub>. The solution was added to a flame-dried round-bottom flask and CH<sub>2</sub>Cl<sub>2</sub> was added to give a total volume of 188 mL. Trimethylsilyl cyanide (10 mL, 75 mmol, 1.2 eq) was added, and the reaction stirred for 15 min. Dimethylcarbamyl chloride (6.9 mL, 75 mmol, 1.2 eq) was added dropwise over 20 min, and the reaction was stirred for 24 h. An additional one equivalent each of trimethylsilylcyanide and dimethylcarbamyl chloride were added, and the reaction was stirred for another 72 h. The reaction was made basic with 10% K<sub>2</sub>CO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3x). The combined organics were dried (MgSO<sub>4</sub>), filtered and concentrated *in vacuo*. Purification by flash chromatography on silica gel afforded 7.2 g (76%) of the title compound as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 8.13 (d, *J* = 1.6 Hz, 1H), 7.82 (d, *J* = 1.7 Hz, 1H), 2.52 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ = 161.99, 144.13, 133.01, 127.65, 126.40, 116.60, 23.57 ppm; LCMS (Method 1): R<sub>T</sub> = 0.715 min, *m/z* = 153.2 [M+H]<sup>+</sup>; HRMS, calc'd for C<sub>7</sub>H<sub>5</sub>ClN<sub>2</sub> [M], 152.0141; found 152.0139.

**6-Methyl-4-(pyrimidin-5-yloxy)picolinonitrile (19a).** Compound **17a** (4.0 g, 26 mmol, 1.0 eq), 5-hydroxypyrimidine **18a** (5.56 g, 57.9 mmol, 2.2 eq), K<sub>2</sub>CO<sub>3</sub> (7.24 mg, 52.4 mmol, 2.0 eq) and DMF (66 mL) were added to a reaction vessel and heated at 80 °C for 16 h. The reaction was filtered and concentrated on silica gel (25 g). The silica gel was loaded on top of a fresh bed of silica gel and washed with 50% EtOAc/hexane. The solvents were removed in vacuo and the crude solid was purified by flash chromatography on silica gel to afford 4.31 g (77%) of the title compound as a pale-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.17 (s, 1H), 8.85 (s, 2H), 7.74 (d, *J* = 2.4 Hz, 1H), 7.32 (d, *J* = 2.3 Hz, 1H), 2.48 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ = 164.04, 162.28, 155.51, 150.02, 148.75, 133.54, 117.05, 115.59, 115.04, 23.82 ppm; LCMS (Method 1): R<sub>T</sub> = 0.535 min, *m/z* = 213.2 [M+H]<sup>+</sup>; HRMS, calc'd for C<sub>11</sub>H<sub>8</sub>N<sub>4</sub>O [M], 212.0698; found 212.0697.

**6-Methyl-4-(pyrimidin-5-yloxy)picolinic acid (20a).** Compound **19a** (4.31 g, 20.3 mmol, 1.0 eq) was dissolved in dioxane (90 mL), and 2N NaOH (45 mL) was added. The mixture was refluxed for 18 h and after cooling the reaction was neutralized with 2N HCl (45 mL). The water and solvent were removed *in vacuo*, and the crude reaction was dissolved in 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub>. The undissolved salt was filtered off and the solvents were removed *in vacuo* to afford 4.65 g (99%) of the title compound as a white solid which was used without further purification.

***N*-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (27).** Compound **20a** (16.84 g, 72.83 mmol, 1.0 eq) and 5-fluoro-2-aminopyridine (16.33 g, 0.15 mol, 2.0 eq) were dissolved in pyridine (485 mL) in a flame-dried round-bottom flask. The reaction was cooled to -

15 °C, and phosphorus oxychloride (7.47 mL, 80.14 mmol, 1.1 eq) was added dropwise while keeping the temperature below -15 °C. After stirring for 30 min at -15 °C, the reaction was quenched with ice-water and neutralized with 10% K<sub>2</sub>CO<sub>3</sub>. The mixture was extracted with EtOAc (3x), and the combined organics were dried (MgSO<sub>4</sub>), filtered, and concentrated *in vacuo*. Purification by flash chromatography on silica gel afforded 14.3 g (60%) of the title compound as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 10.48 (s, 1H), 9.18 (s, 1H), 8.88 (s, 2H), 8.40 (d, *J* = 3.0 Hz, 1H), 8.27 (dd, *J* = 9.2 Hz, 4.10 Hz, 1H), 7.86 (td, *J* = 8.6, 3.1 Hz, 1H), 7.55 (d, *J* = 2.3 Hz, 1H), 7.29 (d, *J* = 2.3 Hz, 1H), 2.58 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ = 165.15, 161.11, 160.57, 156.12 (d, *J*(C,F) = 249.0 Hz), 155.41, 150.29, 150.07, 149.01, 146.92 (d, *J*(C,F) = 2.1 Hz), 135.94 (d, *J*(C,F) = 25.5 Hz), 125.83 (d, *J*(C,F) = 19.9 Hz), 114.56, 114.27 (d, *J*(C,F) = 4.7 Hz), 108.01, 23.84 ppm; LCMS (Method 2): R<sub>T</sub> = 0.727 min, *m/z* = 326.2 [M+H]<sup>+</sup>; HRMS, calc'd for C<sub>16</sub>H<sub>12</sub>FN<sub>5</sub>O<sub>2</sub> [M], 325.0975; found 325.0979.

*The following compounds were prepared analogous to compound 27*

***N*-(4-Methylthiazol-2-yl)-4-(pyrimidin-5-yloxy)picolinamide (10).** LCMS (Method 3): R<sub>T</sub> = 1.147 min, *m/z* = 314.2 [M+H]<sup>+</sup>.

**6-Methyl-*N*-(4-methylthiazol-2-yl)-4-(pyrimidin-5-yloxy)picolinamide (11).** LCMS (Method 2): R<sub>T</sub> = 0.670 min, *m/z* = 328.2 [M+H]<sup>+</sup>.

**4-((5-Fluoropyridin-3-yl)oxy)-*N*-(4-methylthiazol-2-yl)picolinamide (12).** LCMS (Method 2): R<sub>T</sub> = 0.732 min, *m/z* = 331.1 [M+H]<sup>+</sup>.

**4-((5-Fluoropyridin-3-yl)oxy)-6-methyl-*N*-(4-methylthiazol-2-yl)picolinamide (13).**

LCMS (Method 2): R<sub>T</sub> = 0.740 min, *m/z* = 345.1 [M+H]<sup>+</sup>.

**6-Methyl-*N*-(6-methylpyridin-2-yl)-4-(pyrimidin-5-yloxy)picolinamide (21).** LCMS (Method 2):  $R_T = 0.653$  min,  $m/z = 322.2$   $[M+H]^+$ .

**4-((5-Fluoropyridin-3-yl)oxy)-6-methyl-*N*-(6-methylpyridin-2-yl)picolinamide (22).** LCMS (Method 2):  $R_T = 0.730$  min,  $m/z = 339.2$   $[M+H]^+$ .

***N*-(6-Ethylpyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (23).** LCMS (Method 2):  $R_T = 0.624$  min,  $m/z = 336.1$   $[M+H]^+$ .

***N*-(6-Ethylpyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide (24).** LCMS (Method 2):  $R_T = 0.777$  min,  $m/z = 353.2$   $[M+H]^+$ .

***N*-(6-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (25).** LCMS (Method 2):  $R_T = 0.780$  min,  $m/z = 326.1$   $[M+H]^+$ .

***N*-(6-Fluoropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide (26).** LCMS (Method 2):  $R_T = 0.840$  min,  $m/z = 343.2$   $[M+H]^+$ .

***N*-(5-Fluoropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide (28).** LCMS (Method 2):  $R_T = 0.822$  min,  $m/z = 343.1$   $[M+H]^+$ .

***N*-(5-Chloropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (29).** LCMS (Method 2):  $R_T = 0.803$  min,  $m/z = 342.1$   $[M+H]^+$ .

***N*-(5-Chloropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide (30).** LCMS (Method 2):  $R_T = 0.874$  min,  $m/z = 359.1$   $[M+H]^+$ .

***N*-(4-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (31).** LCMS (Method 2):  $R_T = 0.744$  min,  $m/z = 326.2$   $[M+H]^+$ .

***N*-(4-Fluoropyridin-2-yl)-4-((5-fluoropyridin-3-yl)oxy)-6-methylpicolinamide (32).** LCMS (Method 2):  $R_T = 0.822$  min,  $m/z = 343.2$   $[M+H]^+$ .



***N*-(5-Fluoropyridin-2-yl)-6-methyl-4-((2-methylpyrimidin-5-yl)oxy)picolinamide (33).**

LCMS (Method 2):  $R_T = 0.776$  min,  $m/z = 340.2$   $[M+H]^+$ .

**4-((2-Cyclopropylpyrimidin-5-yl)oxy)-*N*-(5-fluoropyridin-2-yl)-6-methylpicolinamide (34).**

LCMS (Method 1):  $R_T = 0.937$  min,  $m/z = 366.2$   $[M+H]^+$ .

**6-(Difluoromethyl)-*N*-(5-fluoropyridin-2-yl)-4-(pyrimidin-5-yloxy)picolinamide (35).** LCMS

(Method 2):  $R_T = 0.765$  min,  $m/z = 362.1$   $[M+H]^+$ .

**4-((5-Chloropyridin-3-yl)oxy)-*N*-(5-fluoropyridin-2-yl)-6-methylpicolinamide (36).** LCMS

(Method 1):  $R_T = 0.942$  min,  $m/z = 359.1$   $[M+H]^+$ .

***N*-(5-Fluoropyridin-2-yl)-6-methyl-4-((6-methylpyridin-3-yl)oxy)picolinamide (37).** LCMS

(Method 1):  $R_T = 0.639$  min,  $m/z = 339.1$   $[M+H]^+$ .

## ASSOCIATED CONTENT

**Supporting Information.** The supporting information is available free of charge on the ACS Publications website at DOI:

Molecular pharmacology methods, complete ancillary pharmacology profile details for **27** and **28**, drug metabolism and pharmacokinetic (DMPK) methods, behavioral pharmacology methods, and *in vivo* occupancy methods.

Molecular formula strings (CSV)

## AUTHOR INFORMATION

**Corresponding Author:** Kyle A. Emmitte

\* Phone: 817-735-0241. Fax: 817-735-2603. E-mail: [kyle.emmitte@unthsc.edu](mailto:kyle.emmitte@unthsc.edu)

**Present Address**

# Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, Fort Worth, Texas 76107, United States.

**Author Contributions**

Drs. Emmitte and Lindsley directed and designed the chemistry. Drs. Felts and Ms. Bates performed the medicinal chemistry. Drs. Conn and Niswender directed and designed the molecular pharmacology experiments. Dr. Rodriguez directed and performed molecular pharmacology experiments. Mr. Venable and Mr. Luscombe performed molecular pharmacology experiments. Dr. Daniels directed and designed the DMPK experiments. Dr. Blobaum directed and designed DMPK experiments and performed bioanalytical work. Mr. Morrison performed bioanalytical work. Mr. Chang performed *in vitro* DMPK work. Mr. Byers performed *in vivo* DMPK work. Dr. Jones directed, designed, and performed behavioral experiments. Dr. Thompson performed behavioral experiments. Dr. Rook designed and performed the rat brain occupancy experiments. Dr. Tantawy performed rat brain occupancy experiments. Dr. Tamagnan was the study director for the NHP brain occupancy study.

**Funding Source**

This work was generously supported by the NIMH U19 MH097056-01 (P.J.C.), NIDA R01 DA023947-01 (C.W.L.), Seaside Therapeutics (VUMC33842), and The William K. Warren Foundation.

**ACKNOWLEDGMENTS**

We gratefully acknowledge the generous support of the National Institute of Mental Health (U19 MH097056-01), the National Institute on Drug Abuse (R01 DA023947-01), Seaside Therapeutics (VUMC33842), and The William K. Warren Foundation for their support of our programs focused on the development of mGlu<sub>5</sub> NAMs.

## ABBREVIATIONS

AD, Alzheimer's disease; AMU, atomic mass units; AMPA,  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AO, aldehyde oxidase; ASD, autism spectrum disorder; AUC, area under the curve; B<sub>max</sub>, maximum amount of radioligand which can bind specifically to the receptors in a membrane preparation; C<sub>max</sub>, maximum concentration; CL<sub>HEP</sub>, predicted hepatic clearance; CL<sub>INT</sub>, intrinsic clearance; CL<sub>p</sub>, plasma clearance; CNS, central nervous system; CRC, concentration response curve; DAT, dopamine transporter; DMF, *N,N*-dimethylformamide; DMPK, drug metabolism and pharmacokinetics; EC<sub>50</sub>, the concentration of agonist that affords a half-maximal response; Et, ethyl; EtOAc, ethyl acetate; FPEB, 3-Fluoro-5-[(pyridin-3-yl)ethynyl]benzonitrile; FST, forced swim test; F, bioavailability; *f*<sub>u</sub>, fraction unbound; FXS, fragile X syndrome; Glu, glutamate; GPCR, G-protein-coupled receptors; h, hours; HEK, human embryonic kidney; HLM, human liver microsomes; HTS, high-throughput screen; IC<sub>50</sub>, the concentration of antagonist at which 50% of receptor function or radioligand binding is inhibited; IND, investigational new drug; IP, intraperitoneal; IV, intravenous; K<sub>i</sub>, the concentration of compound that will bind half of the binding sites at equilibrium; K<sub>p</sub>, brain to plasma ratio; K<sub>p,uu</sub>, unbound brain to unbound plasma ratio; L, liters; LID, levodopa-induced dyskinesia; MDCK, Madin-Darby canine kidney; MDD, major depressive disorder; Me, methyl; mGlu, metabotropic glutamate receptor; MPEP, methyl-6-(phenylethynyl)-pyridine; min,

minutes; MRT, mean residence time; MTEP, 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine; NADPH, nicotinamide adenine dinucleotide phosphate (reduced form); NAM, negative allosteric modulator; NMDA, *N*-methyl-D-aspartate; NHP, non-human primate; Occ<sub>50</sub>, concentration of drug that produces 50% receptor brain occupancy; OCD, obsessive-compulsive disorder, PAM, positive allosteric modulator; PD, Parkinson's disease; PEG, polyethylene glycol; PET, positron emission tomography; P-gp, P-glycoprotein; PK, pharmacokinetics; RO, receptor occupancy; RO<sub>50</sub>, dose of compound that results in 50% receptor occupancy; s, seconds; SAR, structure activity relationships; SEM, standard error of the mean; THF, tetrahydrofuran; TRD, treatment-resistant depression; T<sub>max</sub>, time at which maximum concentration of test compound occurs; t<sub>1/2</sub>, half-life; V<sub>ss</sub>, volume of distribution at steady-state; VFT, venus fly trap; 7TM, seven transmembrane.

## REFERENCES

1. Golubeva, A. V.; Moloney, R.D.; O'Connor, R. M.; Dinan, T. G.; Cryan, J. F. Metabotropic glutamate receptors in central nervous system disease. *Curr. Drug Targets* **2016**, *17*, 538-616.
2. Gregory, K. J.; Noetzel, M. J.; Rook, J. M.; Vinson, P. N.; Stauffer, S. R.; Rodriguez, A. L.; Emmitte, K. A.; Zhou, Y.; Chun, A. C.; Felts, A. S.; Chauder, B. A.; Lindsley, C. W.; Niswender, C. M.; Conn, P. J. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. *Mol. Pharmacol.* **2012**, *82*, 860-875.

3. Lindsley, C. W.; Emmitte, K. A.; Hopkins, C. R.; Bridges, T. M.; Gregory, K. J.; Niswender, C. M.; Conn, P. J. Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors. *Chem. Rev.* **2016**, *116*, 6707-6741.
4. Emmitte, K. A. mGlu<sub>5</sub> negative allosteric modulators: a patent review (2013-2016). *Expert Opin. Ther. Pat.* **2017**, *27*, 691-706.
5. Rocher, J. P.; Bonnet, B.; Boléa, C.; Lütjens, R.; Le Poul, E.; Poli, S.; Epping-Jordan, M.; Bessis, A. S.; Ludwig, B.; Mutel, V. mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutics. *Curr. Top. Med. Chem.* **2011**, *11*, 680-695.
6. Mihov, Y.; Hasler, G. Negative allosteric modulators of metabotropic glutamate receptors subtype 5 in addiction: a therapeutic window. *Int. J. Neuropsychopharmacol.* **2016**, *19*, pii: pyw002.
7. Ribeiro, F. M.; Vieira, L. B.; Pires, R. G.; Olmo, R. P.; Ferguson, S. S. Metabotropic glutamate receptors and neurodegenerative diseases. *Pharmacol Res.* **2017**, *115*, 179-191.
8. Busse, C. S.; Brodtkin, J.; Tattersall, D.; Anderson, J. J.; Warren, N.; Tehrani, L.; Bristow, L. J.; Varney, M. A.; Cosford, N. D. P. The behavioral profile of the potent and selective mGlu<sub>5</sub> receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP) in rodent models of anxiety. *Neuropsychopharmacology* **2004**, *29*, 1971-1979.
9. Silverman, J. L.; Smith, D. G.; Rizzo, S. J.; Karras, M. N.; Turner, S. M.; Tolu, S. S.; Bryce, D. K.; Smith, D. L.; Fonseca, K.; Ring, R. H.; Crawley, J. N. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. *Sci. Transl. Med.* **2012**, *4*, 131ra51.

10. Pop, A. S.; Gomez-Mancilla, B.; Neri, G.; Willemsen, R.; Gasparini, F. Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. *Psychopharmacology (Berl)* **2014**, *231*, 1217-1226.
11. Litim, N.; Morissette, M.; Di Paolo, T. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: an update from the last 5 years of research. *Neuropharmacology* **2016**, *115*, 166-179.
12. Rascol, O.; Fox, S.; Gasparini, F.; Kenney, C.; Di Paolo, T.; Gomez-Mancilla, B. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. *Parkinsonism Relat. Disord.* **2014**, *20*, 947-956.
13. Jaso, B. A.; Niciu, M. J.; Iadarola, N. D.; Lally, N.; Richards, E. M.; Park, M.; Ballard, E. D.; Nugent, A. C.; Machado-Vieira, R.; Zarate, C. A. Therapeutic modulation of glutamate receptors in major depressive disorder. *Curr. Neuropharmacol.* **2017**, *15*, 57-70.
14. Rutrick, D.; Stein, D. J.; Subramanian, G.; Smith, B.; Fava, M.; Hasler, G.; Cha, J.; Gasparini, F.; Donchev, T.; Ocwieja, M.; Johns, D.; Gomez-Mancilla, B. Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study. *Adv. Ther.* **2017**, *34*, 524-541.
15. Gasparini, F.; Lingenhöhl, K.; Stoehr, N.; Flor, P. J.; Heinrich, M.; Vranesic, I.; Biollaz, M.; Allgeier, H.; Heckendorn, R.; Urwyler, S.; Varney, M. A.; Johnson, E. C.; Hess, S. D.; Rao, S. P.; Sacca, A. I.; Santori, E. M.; Veliocelebi, G.; Kuhn, R. Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systematically active mGlu<sub>5</sub> receptor antagonist. *Neuropharmacology* **1999**, *38*, 1493-1503.
16. Cosford, N. D.; Tehrani, L.; Roppe, J.; Schweiger, E.; Smith, N. D.; Anderson, J.; Bristow, L.; Brodtkin, J.; Jiang, X.; McDonald, I.; Rao, S.; Washburn, M.; Varney, M. A. 3-[(2-

- Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. *J. Med. Chem.* **2003**, *46*, 204-206.
17. Porter, R. H. P.; Jaeschke, G.; Spooren, W.; Ballard, T. M.; Büttelmann, B.; Kolczewski, S.; Peters, J. U.; Prinssen, E.; Wichmann, J.; Vieira, E.; Mühlemann, A.; Gatti, S.; Mutel, V.; Malherbe, P. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu<sub>5</sub> receptor antagonist with inverse agonist activity. *J. Pharmacol. Exp. Ther.* **2005**, *315*, 711-721.
18. Berry-Kravis, E. M.; Hessel, D.; Coffey, S.; Hervey, C.; Schneider, A.; Yuhas, J.; Hutchinson, J.; Snape, M.; Tranfaglia, M.; Nguyen, D. V.; Hagerman, R. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. *J. Med. Genet.* **2009**, *46*, 266-721.
19. Swedberg, M. D. B.; Raboisson, P. AZD9272 and AZD2066: selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects. *J. Pharmacol. Exp. Ther.* **2014**, *350*, 212-222.
20. Stähle, L.; Karlsten, R.; Jonzon, B.; Eriksson, B.; Kågedal, M.; Dominicus, A. Safety evaluation of the mGluR5 antagonists AZD9272, AZD2066 and AZD2516 in healthy volunteers and patients with neuropathic pain or major depressive disorders. Abstracts of Papers: 14<sup>th</sup> World Congress on Pain: Milan, Italy; 28 August 2012, Abstract PT444.
21. Vranesic, I.; Ofner, S.; Flor, P. J.; Bilbe, G.; Bouhelal, R.; Enz, A.; Desrayaud, S.; McAllister, K.; Kuhn, R.; Gasparini, F. AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: identification, SAR and pharmacological characterization. *Bioorg. Med. Chem.* **2014**, *22*, 5790-5803.

22. Berry-Kravis, E.; Des Portes, V.; Hagerman, R.; Jacquemont, S.; Charles, P.; Visootsak, J.; Brinkman, M.; Rerat, K.; Koumaras, B.; Zhu, L.; Barth, G. M.; Jaecklin, T.; Apostol, G.; von Raison, F. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. *Sci. Transl. Med.* **2016**, *8*, 321ra5.
23. Trenkwalder, C.; Stocchi, F.; Poewe, W.; Dronamraju, N.; Kenney, C.; Shah, A.; von Raison, F.; Graf, A. Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: two randomized phase 2 studies. *Mov. Disord.* **2016**, *31*, 1054-1058.
24. Stocchi, F.; Rascol, O.; Destee, A.; Hattori, N.; Hauser, R. A.; Lang, A. E.; Poewe, W.; Stacy, M.; Tolosa, E.; Gao, H.; Nagel, J.; Merschhemke, M.; Graf, A.; Kenney, C.; Trenkwalder, C. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. *Mov. Disord.* **2013**, *28*, 1838-1846.
25. Walles, M.; Wolf, T.; Jin, Y.; Ritzau, M.; Leuthold, L. A.; Krauser, J.; Gschwind, H. P.; Carcache, D.; Kittelmann, M.; Ocwieja, M.; Ufer, M.; Woessner, R.; Chakraborty, A.; Swart, P. Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. *Drug Metab. Dispos.* **2013**, *41*, 1626-1641.
26. Jaeschke, G.; Kolczewski, S.; Spooren, W.; Vieira, E.; Bitter-Stoll, N.; Boissin, P.; Borroni, E.; Büttelmann, B.; Ceccarelli, S.; Clemann, N.; David, B.; Funk, C.; Guba, W.; Harrison, A.; Hartung, T.; Honer, M.; Huwyler, J.; Kuratli, M.; Niederhauser, U.; Pähler, A.; Peters, J. U.; Petersen, A.; Prinssen, E.; Ricci, A.; Rueher, D.; Rueher, M.; Schneider, M.; Spurr, P.; Stoll, T.; Tännler, D.; Wichmann, J.; Porter, R. H.; Wettstein, J. G.; Lindemann, L. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1*H*-imidazol-4-ylethynyl]pyridine (basimglurant,



- RO4917523), a promising novel medicine for psychiatric diseases. *J. Med. Chem.* **2015**, *58*, 1358-1371.
27. Guerini, E.; Schadt, S.; Greig, G.; Haas, R.; Husser, C.; Zell, M.; Funk, C.; Hartung, T.; Gloge, A.; Mallalieu, N. L. A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [ $^{14}\text{C}$ ]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [ $^{13}\text{C}_6$ ]-labeled basimglurant in humans. *Xenobiotica* **2017**, *47*, 144-153.
28. Quiroz, J. A.; Tamburri, P.; Deptula, D.; Banken, L.; Beyer, U.; Rabbia, M.; Parkar, N.; Fontoura, P.; Santarelli, L. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. *JAMA Psychiatry* **2016**, *73*, 675-684.
29. Fuxe, K.; Borroto-Escuela, D. O. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. *Expert Opin. Invest. Drugs* **2015**, *24*, 1247-1260.
30. Bezard E.; Pioli, E. Y.; Li, Q.; Girard, F.; Mutel, V.; Keywood, C.; Tison, F.; Rascol, O.; Poli, S. M. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. *Mov. Disord.* **2014**, *29*, 1074-1079.
31. Tison, F.; Keywood, C.; Wakefield, M.; Durif, F.; Corvol, J. C.; Eggert, K.; Lew, M.; Isaacson, S.; Bezard, E.; Poli, S. M.; Goetz, C. G.; Trenkwalder, C.; Rascol, O. A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. *Mov. Disord.* **2016**, *31*, 1373-1380.
32. Palanisamy, G. S.; Marcek, J. M.; Cappon, G. D.; Whritenour, J.; Shaffer, C. L.; Brady, J. T.; Houle, C. Drug-induced skin lesions in cynomolgus macaques treated with metabotropic

- glutamate receptor 5 (mGluR5) negative allosteric modulators. *Toxicol. Pathol.* **2015**, *43*, 995-1003.
33. Morin, N.; Morissette, M.; Grégoire, L.; Gomez-Mancilla, B.; Gasparini, F.; Di Paolo, T. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys. *Neuropharmacology* **2013**, *73*, 216-231.
34. Masilamoni, G. J.; Bogenpohl, J. W.; Alagille, D.; Delevich, K.; Tamagnan, G.; Votaw, J. R.; Wichmann, T.; Smith, Y. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. *Brain* **2011**, *134*, 2057-2073.
35. See page 862 of Zhang, L.; Balan, G.; Barreiro, G.; Boscoe, B. P.; Chenard, L. K.; Cianfroga, J.; Claffey, M. M.; Chen, L.; Coffman, K. J.; Drozda, S. E.; Dunetz, J. R.; Fonseca, K. R.; Galatsis, P.; Grimwood, S.; Lazzaro, J. T.; Mancuso, J. Y.; Miller, E. L.; Reese, M. R.; Rogers, B. N.; Sakurada, I.; Skaddan, M.; Smith, D. L.; Stepan, A. F.; Trapa, P.; Tuttle, J. B.; Verhoest, P. R.; Walker, D. P.; Wright, A. S.; Zaleska, M. M.; Zasadny, K.; Shaffer, C. L. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1*H*-pyrazolo-[3,4-*b*]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. *J. Med. Chem.* **2014**, *57*, 861-877.
36. Bates, B. S.; Rodriguez, A. L.; Felts, A. S.; Morrison, R. D.; Venable, D. F.; Blobaum, A. L.; Byers, F. W.; Lawson, K. P.; Daniels, J. S.; Niswender, C. M.; Jones, C. K.; Conn, P. J.; Lindsley, C. W.; Emmitte, K. A. Discovery of VU0431316: a negative allosteric modulator

- of mGlu<sub>5</sub> with activity in a mouse model of anxiety. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 3307-3314.
37. Felts, A. S.; Rodriguez, A. L.; Morrison, R. D.; Venable, D. F.; Manka, J. T.; Bates, B. S.; Blobaum, A. L.; Byers, F. W.; Daniels, J. S.; Niswender, C. M.; Jones, C. K.; Conn, P. J.; Lindsley, C. W.; Emmitte, K. A. Discovery of VU0409106: a negative allosteric modulator of mGlu<sub>5</sub> with activity in a mouse model of anxiety. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 5779-5785.
38. Crouch, R. D.; Morrison, R. D.; Byers, F. W.; Lindsley, C. W.; Emmitte, K. A.; Daniels, J. S. Evaluating the disposition of a mixed aldehyde oxidase/cytochrome P450 substrate in rats with attenuated P450 activity. *Drug Metab. Dispos.* **2016**, *44*, 1296-1303.
39. Rook, J. M.; Tantawy, M. N.; Ansari, M. S.; Felts, A. S.; Stauffer, S. R.; Emmitte, K. A.; Kessler, R. M.; Niswender, C. M.; Daniels, J. S.; Jones, C. K.; Lindsley, C. W.; Conn, P. J. Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles. *Neuropsychopharmacology* **2015**, *40*, 755-765.
40. Morrison, R. D.; Blobaum, A. L.; Byers, F. W.; Santomango, T. S.; Bridges, T. M.; Stec, D.; Brewer, K. A.; Sanchez-Ponce, R.; Corlew, M. M.; Rush, R.; Felts, A. S.; Manka, J.; Bates, B. S.; Venable, D. F.; Rodriguez, A. L.; Jones, C. K.; Niswender, C. M.; Conn, P. J.; Lindsley, C. W.; Emmitte, K. A.; Daniels, J. S. The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5. *Drug Metab. Dispos.* **2012**, *40*, 1834-1845.
41. Zientek, M.; Miller, H.; Smith, D.; Dunklee, M. B.; Heinle, L.; Thurston, A.; Lee, C.; Hyland, R.; Fahmi, O.; Burdette, D. Development of an in vitro drug-drug interaction assay

- to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. *J. Pharmacol. Toxicol. Methods* **2008**, *58*, 206-214.
42. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. *Pharm. Res.* **1993**, *10*, 1093-1095.
43. Di, L.; Rong, H.; Feng, B. Demystifying brain penetration in central nervous system drug discovery. *J. Med. Chem.* **2013**, *56*, 2-12.
44. Kitamura, S.; Sugihara, K.; Ohta, S. Drug-metabolizing ability of molybdenum hydroxylases. *Drug Metab. Pharmacokinet.* **2006**, *21*, 83-98.
45. Noetzel, M. J.; Rook, J. M.; Vinson, P. N.; Cho, H.; Days, E.; Zhou, Y.; Rodriguez, A. L.; Lavreysen, H.; Stauffer, S. R.; Niswender, C. M.; Xiang, Z.; Daniels, J. S.; Lindsley, C. W.; Weaver, C. D.; Conn, P. J. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. *Mol. Pharmacol.* **2012**, *81*, 120-133.
46. Niswender, C.M.; Johnson, K. A.; Luo, Q.; Ayala, J. E.; Kim, C.; Conn, P. J.; Weaver, C. D. A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. *Mol. Pharmacol.* **2008**, *73*, 1213-1224.
47. LeadProfilingScreen<sup>®</sup> (catalog #68), Eurofins Panlabs, Inc.  
<https://www.eurofinspanlabs.com/Catalog/Products/ProductDetails.aspx?prodId=0aCrd3Mu4RA%3d&path=128&leaf=128&track=Add%2f2%2fPackages%2fMolecular+Packages>  
(accessed April 26, 2017).
48. Zahniser, N. R.; Sorkin, A. Rapid regulation of the dopamine transporter: role in stimulant addiction? *Neuropharmacology* **2004**, *47 SI*, 80-91.



49. Dopamine uptake (catalog #316010), Eurofins Panlabs, Inc.  
<https://www.eurofinspanlabs.com/Catalog/Products/ProductDetails.aspx?prodId=0WVKOLUf1Bw%3d> (accessed April 26, 2017)
50. Cosford, N. D. P.; Roppe, J.; Tehrani, L.; Schweiger, E. J.; Seiders, T. J.; Chaudary, A.; Rao, S.; Varney, M. A. [ $^3\text{H}$ ]-Methoxymethyl-MTEP and [ $^3\text{H}$ ]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 351-354.
51. Rodriguez, A. L.; Nong, Y.; Sekaran, N. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. *Mol. Pharmacol.* **2005**, *68*, 1793-1802.
52. Wang, Q.; Rager, J. D.; Weinstein, K.; Kardos, P. S.; Dobson, G. L.; Li, J.; Hidalgo, I. J. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. *Int. J. Pharm.* **2005**, *288*, 349-359.
53. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. *Biochem. Biophys. Res. Commun.* **1991**, *175*, 880-885.
54. Hutzler, J. M.; Yang, Y.-S.; Albaugh, D.; Fullenwider, C. L.; Schmenk, J.; Fisher, M. B. Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. *Drug Metab. Dispos.* **2012**, *40*, 267-275.
55. ChanTest Cardiac Channel Panel, Charles River Laboratories International, Inc.,  
<http://www.criver.com/products-services/drug-discovery/therapeutic-areas/oncology/safety-assessment/cardiac-risk/cardiac-ion-channel-panel> (accessed April 26, 2017).

56. McCann, J.; Choi, E.; Yamasaki, E.; Ames, B. N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. *Proc. Natl. Acad. Sci. U. S. A.* **1975**, *72*, 5135-5139.
57. Nicolas, L. B.; Kolb, Y.; Prinssen, E. P. M. A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. *Eur. J. Pharmacol.* **2006**, *547*, 106-115.
58. Thomas, A.; Burant, A.; Bui, N.; Graham, D.; Yuva-Paylor, L. A.; Paylor, R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. *Psychopharmacology* **2009**, *204*, 361-373.
59. Slattery, D. A.; Cryan, J. F. Using the rat forced swim test to assess antidepressant-like activity in rodents. *Nat. Protoc.* **2012**, *7*, 1009-1014.
60. Lindemann, L.; Porter, R. H.; Scharf, S. H.; Kuennecke, B.; Bruns, A.; von Kienlin, M.; Harrison, A. C.; Paehler, A.; Funk, C.; Gloge, A.; Schneider, M.; Parrott, N. J.; Polonchuk, L.; Niederhauser, U.; Morairty, S. R.; Kilduff, T. S.; Vieira, E.; Kolczewski, S.; Wichmann, J.; Hartung, T.; Honer, M.; Borroni, E.; Moreau, J. L.; Prinssen, E.; Spooren, W.; Wettstein, J. G.; Jaeschke, G. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. *J. Pharmacol. Exp. Ther.* **2015**, *353*, 213-233.
61. Browne, C. A.; Lucki, I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. *Front. Pharmacol.* **2013**, *4*, 161.  
<http://journal.frontiersin.org/article/10.3389/fphar.2013.00161/full> (accessed Apr 26, 2017).
62. Zanos, P.; Moaddel, R.; Morris, P. J.; Georgiou, P.; Fischell, J.; Elmer, G. I.; Alkondon, M.; Yuan, P.; Pribut, H. J.; Singh, N. S.; Dossou, K. S.; Fang, Y.; Huang, X. P.; Mayo, C. L.;

Wainer, I. W.; Albuquerque, E. X.; Thompson, S. M.; Thomas, C. J.; Zarate, C. A., Jr.; Gould, T. D. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature* **2016**, *533*, 481-486.

63. Pomierny-Chamiolo, L.; Poleszak, E.; Pilc, A.; Nowak, G. NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. *Pharmacol. Rep.* **2010**, *62*, 1186-1190.
64. Wong, D. F.; Waterhouse, R.; Kuwabara, H.; Kim, J.; Brašić, J. R.; Chamroonrat, W.; Stabins, M.; Holt, D. P.; Dannals, R. F.; Hamill, T. G.; Mozley, P. D.  $^{18}\text{F}$ -FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. *J. Nucl. Med.* **2013**, *54*, 1-9.
65. Conn, P. J.; Lindsley, C. W.; Emmitte, Kyle A.; Rodriguez, A. L.; Felts, A. S.; Jones, C. K.; Bates, B. S.; Chauder, B. A. 6-Alkyl-*N*-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. U.S. Patent 9,085,562, July 21, 2015.

## TABLE OF CONTENTS GRAPHIC








Figure 1. Prototypical mGlu5 NAM preclinical tools 1 and 2 and clinically investigated mGlu5 NAMs 3-8.

114x126mm (300 x 300 DPI)





Table 1. Initial pyridine core analogs of 9  
133x50mm (300 x 300 DPI)



Scheme 1. Synthesis of picolinamide analogs 10-13 and 21-37

100x87mm (300 x 300 DPI)




Table 2. Substituted 2-pyridyl amine analogs

94x46mm (300 x 300 DPI)




Table 3. Analogs of compound 27 and 28

181x55mm (300 x 300 DPI)




Table 6. Rat and cynomolgus monkey pharmacokinetics of compounds 27 and 28  
338x190mm (96 x 96 DPI)




Figure 2. Metabolite (38) of 27 identified in rat, cynomolgus monkey, and human hepatic S9 fractions that is produced predominately by AO.

42x18mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3. (A) Ca<sup>2+</sup> mobilization assay CRC for 27 in HEK293A cells expressing human mGlu5; (B) Effects of 27 on glutamate CRC in rat cortical astrocytes; (C) Competition radioligand binding CRC with 27 and [3H]-3-methoxy-5-(pyridin-2-ylethynyl)pyridine (39); (D) Saturation binding experiment: increasing concentrations of [3H]-39 in the presence and absence of multiple concentrations of 27; (E) Saturation binding experiment: Scatchard analysis of bound/free versus bound ligand; (F) Effects of the neutral mGlu5 site ligand 5-methyl-6-(phenylethynyl)-pyridine (40) on the functional inhibition of glutamate responses induced by 27.

423x240mm (120 x 120 DPI)






Figure 4. (A) Dose-dependent inhibition of marble burying with 27; vehicle = 10% polysorbate 80 (IP); male CD-1 mice; n = 10 per treatment group; 15 min pre-treatment; 30 min burying time; \*, p < 0.05 versus vehicle control group, Dunnett's test; bars denote marbles buried; (B) Dose-dependent inhibition of immobility in rats with 27; vehicle = 10% polysorbate 80 (27, intraperitoneal) and sterile saline (ketamine, subcutaneous); male Sprague-Dawley rats; n = 8-10 per treatment group; 30 min pre-treatment; 6 min testing session; \*, p < 0.05 versus vehicle control group, Dunnett's test; bars denote duration of immobility in s.

231x87mm (120 x 120 DPI)




Figure 5. Imaging studies in rodents; n = 4-8 Sprague-Dawley rats; 27 vehicle = 10% polysorbate 80 in 0.5% methyl cellulose; 27 dosed 30 min prior to [18F]-41 (IV); (A) Representative images of [18F]-41 by increasing oral doses of 27 (B) mGlu5 RO obtained with [18F]-41 and increasing oral doses of 27; (C) Unbound maximum plasma concentration of 27 versus mGlu5 RO; (D) Dose of 27 versus mGlu5 RO; \*normalized to the maximum displacement of [18F]-41.

308x178mm (120 x 120 DPI)






Figure 6. Imaging studies in female baboons; subject A received three doses (0.01, 0.1, and 0.18 mg/kg); subject B received two doses (0.03 and 0.56 mg/kg); 27 vehicle = 10% ethanol, 30% PEG 400, 20% hydroxypropyl- $\beta$ -cyclodextrin in water; 27 dosed over 20 min, 30 min prior to [18F]-41 (IV, 3 min bolus) for all doses except the 0.18 mg/kg dose, which was dosed over 2 min, 50 min prior to [18F]-41; (A) mGlu5 RO obtained in two female baboons with [18F]-41 and increasing IV doses of 27; (B) Total maximum plasma concentration of 27 versus mGlu5 RO; (C) Dose of 27 versus mGlu5 RO; (D) Images for subject A averaged from 0-150 min; (E) Images for subject B averaged from 0-180 min.

200x135mm (120 x 120 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



For Table of Contents Only

242x68mm (120 x 120 DPI)